IFRX
Price:
$2.51
Market Cap:
$142.03M
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune dis...[Read more]
Industry
Biotechnology
IPO Date
2017-11-07
Stock Exchange
NASDAQ
Ticker
IFRX
According to InflaRx N.V.’s latest financial reports and current stock price. The company's current PE Ratio is -2.46. This represents a change of 53.87% compared to the average of -1.60 of the last 4 quarters.
The mean historical PE Ratio of InflaRx N.V. over the last ten years is -16.87. The current -2.46 PE Ratio has changed 1.36% with respect to the historical average. Over the past ten years (40 quarters), IFRX's PE Ratio was at its highest in in the June 2022 quarter at 7.54. The PE Ratio was at its lowest in in the June 2016 quarter at -74.08.
Average
-16.87
Median
-4.73
Minimum
-65.76
Maximum
-1.85
Discovering the peaks and valleys of InflaRx N.V. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 308.40%
Maximum Annual PE Ratio = -1.85
Minimum Annual Increase = -93.08%
Minimum Annual PE Ratio = -65.76
Year | PE Ratio | Change |
---|---|---|
2023 | -1.90 | -59.88% |
2022 | -4.73 | 24.00% |
2021 | -3.82 | 16.54% |
2020 | -3.28 | 77.41% |
2019 | -1.85 | -93.08% |
2018 | -26.69 | 308.40% |
2017 | -6.54 | -82.48% |
2016 | -37.30 | -43.27% |
The current PE Ratio of InflaRx N.V. (IFRX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-3.48
5-year avg
-3.11
10-year avg
-16.87
InflaRx N.V.’s PE Ratio is less than Generation Bio Co. (-0.49), less than Kronos Bio, Inc. (-0.67), greater than Erasca, Inc. (-4.56), greater than C4 Therapeutics, Inc. (-2.55), greater than Edgewise Therapeutics, Inc. (-22.36), greater than Kezar Life Sciences, Inc. (-5.00), greater than Fulcrum Therapeutics, Inc. (-15.85), less than Passage Bio, Inc. (-0.58), less than Acumen Pharmaceuticals, Inc. (-1.32), less than Galera Therapeutics, Inc. (-0.08), less than Inozyme Pharma, Inc. (-1.92), less than Eledon Pharmaceuticals, Inc. (18.27), greater than Icosavax, Inc. (-15.78), less than Ocuphire Pharma, Inc. (-2.14), less than Reviva Pharmaceuticals Holdings, Inc. (-1.80), greater than Protalix BioTherapeutics, Inc. (-13.55), greater than EyePoint Pharmaceuticals, Inc. (-3.85), less than SELLAS Life Sciences Group, Inc. (-1.97), greater than Monte Rosa Therapeutics, Inc. (-4.84), greater than Design Therapeutics, Inc. (-7.53), less than Werewolf Therapeutics, Inc. (-1.08), less than Ikena Oncology, Inc. (-1.24), greater than Stoke Therapeutics, Inc. (-6.05),
Company | PE Ratio | Market cap |
---|---|---|
-0.49 | $71.47M | |
-0.67 | $57.32M | |
-4.56 | $726.61M | |
-2.55 | $273.18M | |
-22.36 | $2.80B | |
-5.00 | $47.86M | |
-15.85 | $245.42M | |
-0.58 | $40.24M | |
-1.32 | $107.54M | |
-0.08 | $1.63M | |
-1.92 | $188.22M | |
18.27 | $255.09M | |
-15.78 | $769.04M | |
-2.14 | $31.74M | |
-1.80 | $82.91M | |
-13.55 | $130.33M | |
-3.85 | $500.28M | |
-1.97 | $65.42M | |
-4.84 | $433.13M | |
-7.53 | $359.54M | |
-1.08 | $68.63M | |
-1.24 | $73.83M | |
-6.05 | $599.59M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like InflaRx N.V. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like InflaRx N.V. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is InflaRx N.V.'s PE Ratio?
How is the PE Ratio calculated for InflaRx N.V. (IFRX)?
What is the highest PE Ratio for InflaRx N.V. (IFRX)?
What is the 3-year average PE Ratio for InflaRx N.V. (IFRX)?
What is the 5-year average PE Ratio for InflaRx N.V. (IFRX)?
How does the current PE Ratio for InflaRx N.V. (IFRX) compare to its historical average?